

CytoTools AG successfully places further tranche of convertible bond for a total nominal value of 2.1 million euros, and thus has sufficient liquidity available to realize the planned projects.

Darmstadt, 07. June 2018 – The CytoTools AG (WKN: A0KFRJ; ISIN: DE000A0KFRJ1) has successfully placed a further tranche of convertible bonds, maturing in March 2019, for a total nominal value of EUR 2,100,000.00. Here, the largest portion was taken on by the fund administered by Yorkville Advisors Global, IP. The gross issue proceeds, amounting to about 2.1 million EUR., are to be used in particular for the financing of the pending clinical trial on active substance dosage and the preparation of the phase III trials in Europe, and thus the preparation of the planned marketing of DermaPro®. „By placing the convertible bond, we have been able to ensure the complete financing of the tasks awaiting us“, said a very satisfied Dr. Mark Andre Freyberg, CEO of the CytoTools AG.

The convertible bond is divided into 21 bonds with a nominal value of EUR 100,000.00 each with a coupon of 0.0 %. During the entire term, the bondholders can, at any time, exercise their conversion rights. With the effective exercise of the conversions right, the conversion price amounts to 95.00 % of the arithmetic mean value of the volume-weighted average daily price of the CytoTools AG stock, as reported by Bloomberg, during a period of five successive trading days, ending with the trading day preceding the day when the corresponding exercise notice is submitted.

This information contains specific future oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.

About CytoTools

CytoTools AG is a German biotechnology company focused on translating fundamental biology research on the mechanisms of cell growth and programmed cell death into unique therapies that are designed to treat the cause of the disease rather than the symptoms. The Company has developed a robust and diverse pipeline of disease modifying therapies that comprise proprietary small molecules and biologics. These have the potential to provide new treatment options in dermatology, cardiology and angiology, urology and oncology. CytoTools AG is structured as an investment and holding company and as such holds investments in its subsidiaries DermaTools Biotech GmbH (57%) and CytoPharma GmbH (47%).

Contact:

CytoTools AG
Dr. Mark Andre Freyberg
Klappacher Str. 126
64285 Darmstadt
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-Mail: freyberg@cytotools.de

UBJ. GmbH
Ingo Janssen
Haus der Wirtschaft
Kapstadtring 10
22297 Hamburg
Tel.: +49-40-6378-5410
Fax: +49-40 6378-5423
E-Mail: ir@ubj.de